IDiyas

For the Inventor, By the Inventor

Scotch Plains, NJ, United States of America

David G Melillo

USPTO Granted Patents = 19

Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 182(Granted Patents)


Company Filing History:

goldMedal19 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1978-2005

Loading Chart...
19 patents (USPTO):Explore Patents
1. 6838291 - Radioligand and binding assay (2005-01-04),
2. 5830433 - Radiolabeled growth hormone secretagogue (1998-11-03),
3. 4922007 - Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (1990-05-01),
4. 4758661 - Chiral synthesis of (1988-07-19),
5. 4499278 - Trans-3-carboxymethylene-4-carboxy-5-methyl-delta2-isoxazoline as (1985-02-12),
6. 4473502 - Synthesis of thienamycin via (3SR, 4RS)-3-[1 (1984-09-25),
7. 4467107 - 1-Hydroxyethyl-2-amino pentanedioic acid derivatives (1984-08-21),
8. 4454332 - Hydroxy amino dicarboxylic acids and esters (1984-06-12),
9. 4414155 - Synthesis of thienamycin via esters of (3SR, (1983-11-08),
10. 4375433 - Process for the preparation of (1983-03-01),
11. 4360684 - Process for the preparation of (1982-11-23),
12. 4349687 - Intermediate for synthesis of thienamycin via (3SR, 4RS)-3-[1 (1982-09-14),
13. 4344885 - Intermediate for the preparation of thienamycin (1982-08-17),
14. 4287123 - Synthesis of thienamycin via (3SR, (1981-09-01),
15. 4282148 - Synthesis of thienamycin via esters of (3SR, (1981-08-04),

Title: Unveiling the Innovative Mind of David G Melillo

Introduction:

David G Melillo is a prolific inventor based in Scotch Plains, NJ (US), whose passion for innovation has led to the creation of a remarkable 19 patents. His groundbreaking work in the field of radioligands and binding assays has significantly advanced the realm of pharmaceuticals and medical research.

Latest Patents:

Among his latest patents is the development of a radioligand compound for identifying compounds that bind to the Ichannel, potentially offering new avenues for antiarrhythmic treatments. Additionally, Melillo has also pioneered a radiolabeled growth hormone secretagogue, revolutionizing the characterization of cellular receptors involved in growth hormone secretagogue activity.

Career Highlights:

Currently employed at Merck & Company, Inc., David G Melillo continues to push the boundaries of scientific discovery. His tenure at Merck has been marked by a relentless pursuit of innovation and a steadfast commitment to improving healthcare through groundbreaking inventions.

Collaborations:

Throughout his career, David G Melillo has had the privilege of collaborating with esteemed colleagues such as Kenneth M Ryan and Meyer Sletzinger. Together, they have fostered a culture of creativity and collaboration, leading to the development of cutting-edge solutions in the pharmaceutical industry.

Conclusion:

In conclusion, David G Melillo stands as a shining example of relentless innovation and dedication to scientific excellence. His contributions to the field of radioligands and pharmaceuticals have not only earned him numerous patents but have also cemented his legacy as a visionary inventor shaping the future of medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…